CG400462, a new bacterial enoyl-acyl carrier protein reductase (FabI) inhibitor

International Journal of Antimicrobial Agents

Volumn 30, Issue 5, 2007, Pages 446-451

  Park, Hee Soo ^a,b   Yoon, Yu Min ^a   Jung, Sung Ji ^a   Yun, I Na Rae ^a   Kim, Cheol Min ^b   Kim, Jeong Mi ^b   Kwak, Jin Hwan ^a  

^a Handong University   (South Korea)

^b CrystalGenomics Inc   (South Korea)

Author keywords

Antibacterial activity; Bacterial enoyl acyl carrier protein reductase (FabI); Mode of action; Resistance mechanism

Indexed keywords

AMPICILLIN; CG 400462; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); ENZYME INHIBITOR; ERYTHROMYCIN; GEMIFLOXACIN; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; OXACILLIN; SPARFLOXACIN; TRICLOSAN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIOSTASIS; BACTERIUM MUTANT; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; FATTY ACID SYNTHESIS; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

AMINO ACID SUBSTITUTION; ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); ENZYME INHIBITORS; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 34848874500     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.07.006     Document Type: Article

References (15)

1. Levy S.B., and Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10 Suppl. (2004) S122-S129
2. Cosgrove S.E., Carroll K.C., and Perl T.M. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 39 (2004) 539-545
3. David J.P., Patrick V.W., David J.H., Ji Y., and John T.L. Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. Drug Discov Today 6 (2001) 537-544
4. McMurry L., Oethinger M., and Levy S.B. Triclosan targets lipid synthesis. Nature 394 (1998) 531-532
5. Park H.S., Kim H.J., Seol M.J., Choi D.R., Choi E.C., and Kwak J.H. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother 50 (2006) 2261-2264
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 15th informational supplement. M100-S15. Wayne, PA: CLSI; 2005.
7. Bliss C.I. Statistics in bioassay (1985), Academic Press, Inc., New York, NY
8. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents. Document M26-A (1999), NCCLS, Wayne, PA
9. Kwak J.H., and Weisblum B. Regulation of plasmid pE194 replication: control of cop-repF operon transcription by Cop and of repF translation by countertranscript RNA. J Bacteriol 176 (1994) 5044-5051
10. Ito Y.K.T., and Hiramatsu K. A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 44 (2000) 1549-1555
11. Slater-Radosti C., Van Aller G., Greenwood R., et al. Biochemical and genetic characterisation of the action of triclosan on Staphylococcus aureus. J Antimicrob Chemother 48 (2001) 1-6
12. Marrakchi H., Dewolf W.E., Quinn C., et al. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK). Biochem J 370 (2003) 1055-1062
13. Heath R.J., Yu U.T., Shapiro M.A., et al. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J Biol Chem 275 (2000) 4654-4659
14. Frank F., Yan K., Wallis N.G., et al. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 46 (2002) 3343-3347
15. Brenwald N.P., and Fraise A.P. Triclosan resistance in methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 55 (2003) 141-144